Health-related quality of life (HRQoL) data are limited in patients with advanced basal cell carcinoma. To report HRQoL outcomes based on STEVIE (NCT01367665), a phase 2 study of vismodegib safety in patients with metastatic BCC or locally advanced BCC that is unsuitable for surgery or radiotherapy. Skindex-16 and MD Anderson Symptom Inventory (MDASI) questionnaires were completed at baseline and at three subsequent visits. Clinically meaningful improvement was defined as a ≥10-point decrease from baseline (Skindex-16) or improvement of at least 3 points from baseline (MDASI). HRQoL-evaluable patients with locally advanced BCC (n = 730) had ≥10-point improvements in Skindex-16 emotion domain scores at all time points. Changes in symptom and function scores in these patients or in any domain scores at any time point in patients with metastatic BCC (n = 10) were not clinically meaningful. Of 10 patients with symptomatic metastatic BCC at baseline, six had ≥3-point improvements in MDASI symptom severity. Skindex-16 and MDASI showed improvement in HRQoL in vismodegib-treated patients with locally advanced or metastatic BCC or BCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/ejd.2018.3448 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PRAME Staining of Adnexal Lesions and Common Skin Cancer Types: Biomarker with Potential Diagnostic Utility.
Dermatopathology (Basel)
December 2024
Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.
PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen first identified in tumor-reactive T-cell clones derived from a patient with metastatic melanoma. Immunohistochemistry (IHC) for PRAME is useful for diagnostic purposes to support a suspected diagnosis of melanoma. Anecdotally, PRAME has been observed to stain sebaceous units in glands in background skin.
View Article and Find Full Text PDFImmunotherapy for locally advanced and metastatic basal cell carcinoma: a narrative review.
Transl Cancer Res
November 2024
Department of Dermatology, Binhaiwan Central Hospital of Dongguan, Dongguan, China.
Background And Objective: Basal cell carcinoma (BCC) is the most common malignancy of humankind, characterized by its low propensity for metastasis and its high recurrence rate. Surgical intervention is the predominant therapeutic approach. However, for cases of locally advanced BCC (laBCC) and metastatic BCC (mBCC), systematic therapy may be the first option.
View Article and Find Full Text PDFA Large Basal Cell Carcinoma Treated With Hedgehog Inhibitor: A Case Report.
Cureus
November 2024
Dermatology, Dermatology Associates of Uptown, Cedar Hill, USA.
Basal cell carcinoma (BCC) is the most commonly diagnosed cutaneous cancer globally. Chronic exposure to environmental triggers and genetic predisposition are risk factors that contribute to the incidence of BCC. While most cases of BCC are treated surgically with curettage or simple excision, treatment options for advanced BCC, including metastatic BCC and locally advanced BCC, are limited as some may be considered unresectable.
View Article and Find Full Text PDFMethylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy.
NPJ Precis Oncol
November 2024
Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.
Article Synopsis
- This study explores blood biomarkers that can predict responses to immune checkpoint inhibitors (ICIs) for patients with recurrent/metastatic head and neck squamous cell carcinoma, addressing challenges like tumor sample variability.
- Researchers enrolled 100 patients and analyzed blood immune profiles, focusing on factors like tumor mutational burden (TMB) and PD-L1 scores, with a goal to find associations with treatment outcomes.
- Key findings revealed that high levels of neutrophils and monocytes were linked to worse survival, while higher CD4T cells correlated with better outcomes, highlighting the potential of using blood tests for predicting ICI treatment responses.
Secondary cutaneous malignancy after treatment of basal cell carcinoma with hedgehog pathway inhibitor: a systematic review.
Arch Dermatol Res
October 2024
Department of Dermatology, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Several studies have been published describing development of cutaneous malignancy after vismodegib therapy; no systematic review has been conducted to interpret these data. Our objective was to systemically review reported cases of same-site or different-site cutaneous malignancy after smoothened inhibitor (SMOi) therapy for primary basal cell carcinoma (BCC). PubMed, CINAHL, and Scopus were systematically searched January 1, 2012 - March 28, 2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!